Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149521 (chronic pancreatitis)
 7,199 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Breath hydrogen (H2) exhalation after xylose administration reflects the malabsorbed portion of the pentose and thus might facilitate the application of the D-xylose test. Therefore, as a complementary parameter, breath H2-exhalation in response to 25 g D-xylose was assessed in control subjects, in patients with coeliac disease, with chronic pancreatitis and with the irritable bowel syndrome. Patients with coeliac disease showed significantly higher breath H2 concentrations than the controls. Specificity and the positive predictive value of peak H2-increments greater than 56 ppm (i.e. greater than mean + 2 SD of controls) were 100%, but sensitivity was only 40%. In all patients with a positive H2 breath test, urinary D-xylose excretion and serum D-xylose increments were also abnormal. Apart from great overlap between controls and patients with coeliac disease, the failure to produce H2 in response to D-xylose in 12% of the 57 investigated subjects was the major factor limiting diagnostic efficiency of the test. Non H2 production could be shown to reflect a specific metabolic disability of the colonic flora and did not prove complete absorption of the substrate. It is concluded, that the 25 g D-xylose H2 breath test is of no clinical relevance for the diagnosis of celiac sprue but exaggerated breath H2 increases (greater than 56 ppm) with normal urinary and D-xylose tests were indicative for the irritable bowel syndrome in 5 out of 10 patients. The diagnostic impact of this constellation thus merits further investigation.
 ...
PMID:Clinical evaluation of a 25 g D-xylose hydrogen (H2) breath test. 227 52

To obtain higher specificity of peptide-PABA-test, an indirect pancreatic functions test, 150 mg N-BT-PABA together with 25 g D-Xylose in 300 ml tea were administered to a group of 68 persons. Maximal concentration of PABA and D-Xylose were investigated serum by time-concentration-curves 0, 60, 90, 120 and 150 min after test meal. Serum-PABA was found pathologically low in 18 of 20 patients with proofed chronic pancreatitis. In 16 of 17 patients with chronic pancreatitis serum-D-Xylose was normal. In a group of 39 patients, in which a pancreatic disease was excluded, PABA-serum-test showed no false-pathological results. In 7 patients with small-bowel diseases and pathological D-Xylose-test, PABA-serum-test was false-pathologically in 6/7 cases. By serum-PABA-time-concentration-curves there was a significant discrimination between patients with chronic pancreatitis and controls at 60, 90, 120 and 150 min (p less than 0.01), but early and late peak concentration of PABA was often found in the two groups. If the PABA-concentration was estimated only 120 min after test meal, diminished test-specificity was found. Peak-PABA-serum-concentration was significantly correlated with lipase output (p less than 0.001) and trypsin output (p = 0.01) at secretin-caerulein test, but PABA was only at low enzyme outputs pathological, showing a moderate sensitivity of test.
 ...
PMID:[Improvement in the specificity of the PABA test (PFT) by combined PABA peptide/D-xylose administration and serum kinetic measurement?]. 387 35